Dimerix Announces License Agreement for EU, Canada, ANZ
Filed with ASX · · 5 pages · English
In the deck
Earlier from Dimerix
- FDA Approves Qytovra Brand Name
- Regulatory Approval received in Malaysia for ACTION3 Study
- Dimerix Receives $8.9M R&D Tax Incentive Rebate
- Successful Completion of 2nd DSMB Review of FSGS Trial
- DMX-200 FSGS PH3 Kidney Trial Part 1 Outcome set for Q1 CY24
Later from Dimerix
- Dimerix Receives Initial Upfront Payment from Advanz Pharma
- ACTION3 IND Approved in China
- Half-Year Financial Report & Appendix 4D - 31 December 2023
- PH3 Data Collection Complete for First Interim Analysis
- Dimerix Successfully Passes Efficacy Interim Analysis
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix